HRP20211032T1 - Postupci za uporabu agonista fxr - Google Patents
Postupci za uporabu agonista fxr Download PDFInfo
- Publication number
- HRP20211032T1 HRP20211032T1 HRP20211032TT HRP20211032T HRP20211032T1 HR P20211032 T1 HRP20211032 T1 HR P20211032T1 HR P20211032T T HRP20211032T T HR P20211032TT HR P20211032 T HRP20211032 T HR P20211032T HR P20211032 T1 HRP20211032 T1 HR P20211032T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- dose
- liver disease
- unit dosage
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 208000019423 liver disease Diseases 0.000 claims 5
- 201000001883 cholelithiasis Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- VYLOOGHLKSNNEK-JWTNVVGKSA-N 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1SC3=CC(=CC(F)=C3N=1)C(O)=O)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F VYLOOGHLKSNNEK-JWTNVVGKSA-N 0.000 claims 2
- 206010056375 Bile duct obstruction Diseases 0.000 claims 2
- 206010008635 Cholestasis Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000001130 gallstones Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Spoj, naznačen time, što je predstavljen formulom (I)
[image]
stereoizomer, enantiomer, njegova farmaceutski prihvatljiva sol ili njegov aminokiselinski konjugat, i što je za uporabu u liječenju ili prevenciji kronične bolesti jetre ili poremećaja jetre, pri čemu se navedeni spoj daje u dozi u rasponu od oko 3 µg do oko 120 µg.
2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, što se navedeni spoj daje u dozi u rasponu od oko 30 µg do oko 90 µg.
3. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, što se navedeni spoj daje u dozi u rasponu od oko 60 µg do oko 120 µg.
4. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time, što je kronična bolest jetre nealkoholna bolest masne jetre (NAFLD), nealkoholni steatohepatitis (NASH), ozljeda žučnog kanala izazvana supstancom, žučni kamenci, ciroza jetre, alkoholom izazvana ciroza, cistična fibroza, opstrukcija žučnih kanala, kolelitijaza ili fibroza jetre.
5. Spoj za uporabu prema patentnom zahtjevu 4, naznačen time, što je kronična bolest jetre nealkoholni steatohepatitis (NASH).
6. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, što je doza dnevna doza.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, što je doza, doza dva puta dnevno.
8. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, što se doza daje svaka dva dana.
9. Spoj za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što je FXR agonistički spoj 2-[(1R,3r,5S)-3-({5-ciklopropil-3-[2-(trifluorometoksi)fenil]-1,2-oksazol-4-il}metoksi)-8-azabiciklo[3.2.1]oktan-8-il]-4-fluoro-1,3-benzotiazol-6-karboksilna kiselina, u slobodnom obliku ili njegov konjugat s aminokiselinom.
10. Pripravak farmaceutskog jediničnog oblika doziranja, naznačen time, što sadrži oko 10 µg, oko 30 µg, oko 60 µg, oko 90 µg ili oko 120 µg 2-[(1R,3r,5S)-3-({5-ciklopropil-3-[2-(trifluorometoksi)fenil]-1,2-oksazol-4-il}metoksi)-8-azabiciklo[3.2.1]oktan-8-il]-4-fluoro-1,3-benzotiazol-6-karboksilne kiseline, za oralnu primjenu do maksimalne ukupne doze od oko 120 µg dnevno.
11. Pripravak farmaceutskog jediničnog oblika doziranja prema patentnom zahtjevu 10, naznačen time, što je 2-[(1R,3r,5S)-3-({5-ciklopropil-3-[2-(trifluorometoksi)fenil]-1,2-oksazol-4-il}metoksi)-8-azabiciklo[3.2.1]oktan-8-il]-4-fluoro-1,3-benzotiazol-6-karboksilna kiselina u slobodnom obliku ili u obliku njezine farmaceutski prihvatljive soli ili je konjugat s aminokiselinom.
12. Pripravak farmaceutskog jediničnog oblika doziranja prema patentnom zahtjevu 10, naznačen time, što se nalazi u obliku odabranom od tekućine, tablete ili kapsule.
13. Pripravak farmaceutskog jediničnog oblika doziranja prema bilo kojem od patentnih zahtjeva 10-12, naznačen time, što je za uporabu u liječenju kronične bolesti jetre, npr. bolesti nealkoholne masne jetre (NAFLD), nealkoholnog steatohepatitisa (NASH), ozljede žučnog kanala uzrokovane supstancom, žučnih kamenaca, ciroze jetre, ciroze izazvane alkoholom, cistične fibroze, opstrukcije žučnih kanala, kolelitijaze, fibroze jetre.
14. Pripravak farmaceutskog jediničnog oblika doziranja prema patentnom zahtjevu 13, naznačen time, što je za uporabu u liječenju nealkoholnog steatohepatitisa (NASH).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298121P | 2016-02-22 | 2016-02-22 | |
| US201662420661P | 2016-12-12 | 2016-12-12 | |
| PCT/IB2017/050963 WO2017145041A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
| EP17709189.9A EP3419625B1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211032T1 true HRP20211032T1 (hr) | 2021-10-01 |
Family
ID=58231666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211032TT HRP20211032T1 (hr) | 2016-02-22 | 2021-06-29 | Postupci za uporabu agonista fxr |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11344540B2 (hr) |
| EP (2) | EP3848031A1 (hr) |
| JP (1) | JP6986022B2 (hr) |
| KR (1) | KR20180115270A (hr) |
| CN (2) | CN108697702A (hr) |
| AU (1) | AU2017223155B2 (hr) |
| BR (1) | BR112018016310A2 (hr) |
| CA (1) | CA3013186A1 (hr) |
| CL (1) | CL2018002359A1 (hr) |
| CY (1) | CY1124300T1 (hr) |
| DK (1) | DK3419625T3 (hr) |
| ES (1) | ES2878575T3 (hr) |
| HK (1) | HK1257647A1 (hr) |
| HR (1) | HRP20211032T1 (hr) |
| HU (1) | HUE054819T2 (hr) |
| IL (1) | IL260784B (hr) |
| LT (1) | LT3419625T (hr) |
| MX (1) | MX2018010100A (hr) |
| PH (1) | PH12018501656A1 (hr) |
| PL (1) | PL3419625T3 (hr) |
| PT (1) | PT3419625T (hr) |
| RU (1) | RU2743075C2 (hr) |
| SI (1) | SI3419625T1 (hr) |
| TW (1) | TWI735546B (hr) |
| WO (1) | WO2017145041A1 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62110B1 (sr) | 2015-03-31 | 2021-08-31 | Enanta Pharm Inc | Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe |
| US11110083B2 (en) | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| GB201616670D0 (en) * | 2016-09-30 | 2016-11-16 | Innospec Ltd | Methods, compositions and uses relating thereto |
| WO2018067704A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| EP3704112B1 (en) | 2017-11-01 | 2023-09-27 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
| US10730863B2 (en) | 2017-11-01 | 2020-08-04 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid X receptor modulators |
| KR20200081435A (ko) | 2017-11-01 | 2020-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| KR20200083528A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| WO2019106550A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Fxr agonists for the treatment of liver diseases |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US20220227804A1 (en) * | 2019-05-29 | 2022-07-21 | Qing Bile Therapeutics Inc. | Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021044351A1 (en) * | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
| CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CU24375B1 (es) | 2013-11-05 | 2018-12-05 | Novartis Ag | Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x |
| WO2015124727A1 (en) | 2014-02-20 | 2015-08-27 | Merck Patent Gmbh | Fgf-18 compound dosing regimen |
| CN108697704A (zh) * | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| US11110083B2 (en) | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
-
2017
- 2017-02-20 CN CN201780010381.3A patent/CN108697702A/zh active Pending
- 2017-02-20 AU AU2017223155A patent/AU2017223155B2/en not_active Ceased
- 2017-02-20 PL PL17709189T patent/PL3419625T3/pl unknown
- 2017-02-20 EP EP21152135.6A patent/EP3848031A1/en not_active Withdrawn
- 2017-02-20 CN CN202111030869.7A patent/CN113679718A/zh active Pending
- 2017-02-20 WO PCT/IB2017/050963 patent/WO2017145041A1/en active Application Filing
- 2017-02-20 SI SI201730836T patent/SI3419625T1/sl unknown
- 2017-02-20 MX MX2018010100A patent/MX2018010100A/es unknown
- 2017-02-20 US US16/078,409 patent/US11344540B2/en active Active
- 2017-02-20 JP JP2018544236A patent/JP6986022B2/ja active Active
- 2017-02-20 EP EP17709189.9A patent/EP3419625B1/en active Active
- 2017-02-20 ES ES17709189T patent/ES2878575T3/es active Active
- 2017-02-20 KR KR1020187023682A patent/KR20180115270A/ko unknown
- 2017-02-20 PT PT177091899T patent/PT3419625T/pt unknown
- 2017-02-20 HU HUE17709189A patent/HUE054819T2/hu unknown
- 2017-02-20 BR BR112018016310-4A patent/BR112018016310A2/pt not_active Application Discontinuation
- 2017-02-20 CA CA3013186A patent/CA3013186A1/en active Pending
- 2017-02-20 LT LTEP17709189.9T patent/LT3419625T/lt unknown
- 2017-02-20 RU RU2018133298A patent/RU2743075C2/ru active
- 2017-02-20 DK DK17709189.9T patent/DK3419625T3/da active
- 2017-02-22 TW TW106105850A patent/TWI735546B/zh not_active IP Right Cessation
-
2018
- 2018-07-25 IL IL260784A patent/IL260784B/en unknown
- 2018-08-03 PH PH12018501656A patent/PH12018501656A1/en unknown
- 2018-08-17 CL CL2018002359A patent/CL2018002359A1/es unknown
-
2019
- 2019-01-02 HK HK19100005.2A patent/HK1257647A1/zh unknown
-
2021
- 2021-06-29 HR HRP20211032TT patent/HRP20211032T1/hr unknown
- 2021-07-05 CY CY20211100600T patent/CY1124300T1/el unknown
-
2022
- 2022-04-26 US US17/660,673 patent/US20220313677A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211032T1 (hr) | Postupci za uporabu agonista fxr | |
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| ES2772754T3 (es) | Pemafibrato para uso en el tratamiento de la enfermedad del hígado graso no alcohólico | |
| JP2018021046A5 (hr) | ||
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| FR19C1030I1 (fr) | Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles | |
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| JP2018507914A5 (hr) | ||
| JP2009530413A5 (hr) | ||
| HRP20110271T1 (hr) | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) | |
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2015038135A5 (hr) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2016511753A5 (hr) | ||
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| TW201735923A (zh) | 使用fxr促效劑之方法 | |
| RU2019113150A (ru) | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения | |
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2013508282A (ja) | ウイルス感染のための併用療法処置 |